Antimicrobial resistance (AMR) is a global health threat, urgently requiring novel compounds with new targets. One emerging strategy is the development of ‘antibiotic adjuvants’ that inhibit the mutagenic SOS response in bacteria, thus prolonging antibiotic efficacy. OXF‑077 is a potent SOS-response...
To combat methicillin-resistant Staphylococcus aureus (MRSA) infections novel drugs addressing unprecedented and resistance-free targets are desperately needed. From a screen of human kinase inhibitors, we find that the anti-cancer drug sorafenib effectively kills MRSA strains. By dissection of the ...
